Expressional and Prognostic Value of S100A16 in Pancreatic Cancer Via Integrated Bioinformatics Analyses

Gangping Tu; Wenzhe Gao; Ying Li; Yating Dian; Bingyang Xue; Li Niu; Xiao Yu; Hongwei Zhu

doi:10.3389/fcell.2021.645641

Expressional and Prognostic Value of S100A16 in Pancreatic Cancer Via Integrated Bioinformatics Analyses

Front Cell Dev Biol. 2021 Apr 12:9:645641. doi: 10.3389/fcell.2021.645641. eCollection 2021.

Authors

Gangping Tu¹, Wenzhe Gao¹, Ying Li², Yating Dian², Bingyang Xue², Li Niu², Xiao Yu¹, Hongwei Zhu¹

Affiliations

¹ Department of Hepatopancreatobiliary Surgery, The Third Xiangya Hospital, Central South University, Changsha, China.
² Medical College of Xiangya, Central South University, Changsha, China.

Abstract

Studies have shown that the calcium-binding protein family S100 may play a role in the development of pancreatic cancer (PC), but the role of S100A16 in PC is still unknown. In this study, Oncomine was first used to detect the expression level and prognosis of S100A16 in PC and other tumors. The results showed that S100A16 was highly expressed in PC tissues compared with a normal pancreas, and the increased expression level may be related to poor prognosis in PC patients. The TCGA and ICGC RNA-seq data of PC patients were downloaded, and the S100A16-related differentially expressed genome (DEGs) was defined by taking the intersection of two gene sets. The GO and KEGG pathways were then analyzed. For clinical analysis, boxplots were depicted for the correlation between clinical characteristics and S100A16 expression. Then Cox regression was applied for exploring the prognostic value of S100A16 for PDAC patients. Based on the Cox regression model, we further estabished a S100A16-related risk score system to strengthen the ability to predict patients' prognosis. After integrating the risk score model and multiple clinicopathological factors, we finally established a nomogram that could predict the survival time of patients. Moreover, Gene set enrichment the effect of S100A16 expression differences on downstream biological processes. At last, using TIMER, ImmuneCellAI and GSEA we analyzed the correlation between S100A16 and pancreatic cancer immune infiltration and predicted the response of patients to checkpoint Blocker (ICB). In summary, S100A16 is involved in the occurrence and development of PC, affecting the prognosis of patients, and may have potential reference values for the immunotherapy of PC.

Keywords: S100A16; TCGA; immune infiltration; pancreatic adenocarcinoma; prognosis.